Merus N.V. (MRUS) officer exits as Genmab pays $97 per share in cash
Rhea-AI Filing Summary
Merus N.V.’s VP Controller and Principal Accounting Officer reported the cash-out of all personal equity in connection with Genmab’s tender offer. On December 12, 2025, the officer tendered 11,002 common shares, which were accepted at $97.00 per share in cash, leaving no common shares beneficially owned afterward. Previously granted employee stock options covering various numbers of common shares at exercise prices between $13.23 and $41.65 were cancelled on the same date and converted into cash equal to their in-the-money value based on the $97.00 offer price.
Positive
- None.
Negative
- None.
Insights
Genmab’s tender offer cashes out a Merus officer’s shares and options at $97.
The disclosure shows that a wholly owned Genmab subsidiary completed a tender offer for all issued and outstanding common shares of Merus N.V.. Under a transaction agreement signed on September 29, 2025, the purchaser accepted all validly tendered shares at an offer consideration of $97.00 per share in cash, without interest and less applicable withholding taxes, as of the acceptance time on December 12, 2025.
For this reporting person, the event meant a full exit from Merus equity. They tendered 11,002 common shares at $97.00 per share, and the table shows 0 shares beneficially owned afterward. Multiple employee stock options with exercise prices ranging from $13.23 to $41.65 and covering thousands of underlying shares were cancelled and exchanged for cash equal to the excess of the $97.00 offer price over each option’s exercise price, multiplied by the number of underlying shares.
This structure is typical for a change-of-control transaction in which all participating shareholders receive the same fixed cash price, and outstanding options are settled for their intrinsic value. For holders who participate in the offer, economic exposure shifts from future share price movements to the immediate cash proceeds determined by the $97.00 per share consideration.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Share Option (right to buy) | 7,600 | $0.00 | -- |
| Disposition | Share Option (right to buy) | 16,000 | $0.00 | -- |
| Disposition | Share Option (right to buy) | 4,700 | $0.00 | -- |
| Disposition | Share Option (right to buy) | 12,400 | $0.00 | -- |
| Disposition | Share Option (right to buy) | 5,000 | $0.00 | -- |
| Disposition | Share Option (right to buy) | 14,500 | $0.00 | -- |
| Disposition | Share Option (right to buy) | 23,420 | $0.00 | -- |
| Disposition | Share Option (right to buy) | 700 | $0.00 | -- |
| Disposition | Share Option (right to buy) | 27,550 | $0.00 | -- |
| Disposition | Share Option (right to buy) | 500 | $0.00 | -- |
| U | Common Shares | 11,002 | $97.00 | $1.07M |
Footnotes (1)
- On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time, including the Shares tendered by the reporting person, in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time. This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option.
FAQ
What insider transaction did Merus N.V. (MRUS) report for its VP Controller?
The VP Controller and Principal Accounting Officer of Merus N.V. reported tendering 11,002 common shares, which were accepted for $97.00 per share in cash in connection with Genmab’s tender offer.
What happened to the Merus N.V. stock options held by the reporting person?
The reporting person’s stock options, covering various numbers of Merus common shares at exercise prices from $13.23 to $41.65, were cancelled and converted into cash equal to the in-the-money value based on the $97.00 offer price.
Who is acquiring Merus N.V. through the tender offer described in this insider report?
The tender offer for all issued and outstanding Merus N.V. common shares was commenced by a wholly owned subsidiary of Genmab A/S, pursuant to a transaction agreement dated September 29, 2025.